New insights into mechanisms of therapeutic effects of antimalarial agents in SLE

Nature Reviews Rheumatology

Volumn 8, Issue 9, 2012, Pages 522-533

  Wallace, Daniel J ^a   Gudsoorkar, Vineet S ^a   Weisman, Michael H ^a   Venuturupalli, Swamy R ^a  

^a Cedarsg Sinai Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; MATRIX METALLOPROTEINASE; MEPACRINE; PERILIPIN; PLACEBO; STEROID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ACCOMMODATION PARALYSIS; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APLASTIC ANEMIA; CATARACT; DEPIGMENTATION; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HAIR LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; KERATOPATHY; KIDNEY INJURY; LACTATION; LEUKOPENIA; LIGHT ABSORPTION; LIVER DYSFUNCTION; LONG TERM CARE; MACULOPAPULAR RASH; MORBIDITY; NAUSEA; NERVOUSNESS; NEUROPATHY; NIGHTMARE; NONHUMAN; OVERALL SURVIVAL; PATIENT COMPLIANCE; PORPHYRIA; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SEIZURE; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN PIGMENTATION; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION; THROMBOSIS; TINNITUS; VESTIBULAR DISORDER; VOMITING;

ADULT; ANTIMALARIALS; FEMALE; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; HYPOLIPIDEMIC AGENTS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LACTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME;

EID: 84866103485     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.106     Document Type: Review

References (107)

1. Wallace, D. J. The history of antimalarials. Lupus 5 (Suppl. 1), S2-S3 (1996 (Pubitemid 26196733)
2. Knox, C. et al. DrugBank 3.0: A comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011
3. Tett, S. E., McLachlan, A. J., Cutler, D. J. & Day, R. O. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6, 355-359 (1994 (Pubitemid 24215102)
4. Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5 (Suppl. 1), S11-S15 (1996 (Pubitemid 26196735)
5. Scherbel, A. L., Schuchter, S. L. & Harrison, J. W. Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis. Cleve. Clin. Q. 24, 98-104 (1957
6. Block, J. A. Hydroxychloroquine and retinal safety. Lancet 351, 771 (1998 (Pubitemid 28112335)
7. Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284-3290 (2006 (Pubitemid 44622099)
8. Costedoat-Chalumeau, N. et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66, 821-824 (2007 (Pubitemid 46846706)
9. Wallace, D. J. Antimalarials - the 'real' advance in lupus. Lupus 10, 385-387 (2001 (Pubitemid 32578610)
10. Fox, R. I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis Rheum. 23, 82-91 (1993
11. Wallace, D. J., Linker-Israeli, M., Hyun, S., Klinenberg, J. R. & Stecher, V. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J. Rheumatol. 21, 375-376 (1994 (Pubitemid 24078865)
12. Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P. & Sysa-Jedrzejowska, A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15, 268-275 (2006 (Pubitemid 43828802)
13. Jang, C. H., Choi, J. H., Byun, M. S. & Jue, D. M. Chloroquine inhibits production of TNF-α, IL1β and IL6 from lipopolysaccharide- stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 45, 703-710 (2006
14. Wozniacka, A. et al. The influence of antimalarial treatment on IL1β, IL6 and TNF-α mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol. 159, 1124-1130 (2008
15. Napirei, M. et al. Features of systemic lupus erythematosus in DNase1-deficient mice. Nat. Genet. 25, 177-181 (2000 (Pubitemid 30394988)
16. Chitrabamrung, S., Rubin, R. L. & Tan, E. M. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol. Int. 1, 55-60 (1981 (Pubitemid 11038705)
17. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835 (2006 (Pubitemid 44631651)
18. Blasius, A. L. & Beutler, B. Intracellular Toll-like receptors. Immunity 32, 305-315 (2010
19. Vallin, H., Blomberg, S., Alm, G. V., Cederblad, B. & Ronnblom, L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 115, 196-202 (1999 (Pubitemid 29030385)
20. Ronnblom, L. & Alm, G. V. The natural interferon-α producing cells in systemic lupus erythematosus. Hum. Immunol. 63, 1181-1193 (2002 (Pubitemid 36025993)
21. Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20. (2011
22. Bird, A. P., Taggart, M. H., Nicholls, R. D. & Higgs, D. R. Non-methylated CpG-rich islands at the human α-globin locus: Implications for evolution of the α-globin pseudogene. Embo J. 6, 999-1004 (1987
23. Cornelie, S. et al. Direct evidence that Toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition. J. Biol. Chem. 279, 15124-15129 (2004 (Pubitemid 38618907)
24. Hong, Z. et al. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int. Immunopharmacol. 4, 223-234 (2004 (Pubitemid 38296351)
25. Macfarlane, D. E. & Manzel, L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160, 1122-1131 (1998 (Pubitemid 28093406)
26. Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575-1585 (2005 (Pubitemid 41746603)
27. de Bouteiller, O. et al. Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J. Biol. Chem. 280, 38133-38145 (2005 (Pubitemid 43853708)
28. Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658-662 (2008
29. Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794-4804 (2011
30. Furukawa, F., Kashihara-Sawami, M., Lyons, M. B. & Norris, D. A. Binding of antibodies to the extractable nuclear antigens SSA/Ro and SSB/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): Implications for the pathogenesis of photosensitive cutaneous lupus. J. Invest. Dermatol. 94, 77-85 (1990 (Pubitemid 20046045)
31. Shaffer, B., Cahn, M. M. & Levy, E. J. Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium. J. Invest. Dermatol. 30, 341-345 (1958
32. Nguyen, T. Q., Capra, J. D. & Sontheimer, R. D. 4aminoquinoline antimalarials enhance UVB induced cJun transcriptional activation. Lupus 7, 148-153 (1998 (Pubitemid 28190677)
33. Wallace, D. J., Metzger, A. L., Stecher, V. J., Turnbull, B. A. & Kern, P. A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am. J. Med. 89, 322-326 (1990 (Pubitemid 20323259)
34. Goldstein, J. L., Brunschede, G. Y. & Brown, M. S. Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339. J. Biol. Chem. 250, 7854-7862 (1975
35. Lange, Y., Duan, H. & Mazzone, T. Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci. J. Lipid Res. 37, 534-539 (1996 (Pubitemid 26134359)
36. Gu, J. Q. et al. A Toll-like receptor 9mediated pathway stimulates perilipin 3 (TIP47) expression and induces lipid accumulation in macrophages. Am. J. Physiol. Endocrinol. Metab. 299, E593-E600 (2010
37. Tobias, P. & Curtiss, L. K. Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: Toll receptors in atherogenesis. J. Lipid Res. 46, 404-411 (2005 (Pubitemid 43109775)
38. Lesiak, A. et al. Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis. Clin. Exp. Dermatol. 34, 570-575 (2009
39. Pinhal-Enfield, G. et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A2A receptors. Am. J. Pathol. 163, 711-721 (2003 (Pubitemid 36909432)
40. Espinola, R. G., Pierangeli, S. S., Gharavi, A. E. & Harris, E. N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 87, 518-522 (2002 (Pubitemid 34232495)
41. Rand, J. H. et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood 115, 2292-2299 (2010
42. Woessner, J. F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J. 5, 2145-2154 (1991 (Pubitemid 21905847)
43. Stuhlmeier, K. M. & Pollaschek, C. Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism. J. Rheumatol. 33, 472-480 (2006 (Pubitemid 43334567)
44. Lesiak, A. et al. Effect of chloroquine phosphate treatment on serum MMP9 and TIMP1 levels in patients with systemic lupus erythematosus. Lupus 19, 683-688 (2010
45. Merrell, M. A. et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res. 4, 437-447 (2006 (Pubitemid 44197039)
46. Lullmann-Rauch, R., Pods, R. & von Witzendorff, B. The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo. Toxicology 110, 27-37 (1996 (Pubitemid 26168361)
47. Toubi, E. et al. The reduction of serum Blymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand. J. Immunol. 63, 299-303 (2006
48. Ehsanian, R., Van Waes, C. & Feller, S. M. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun. Signal. 9, 13 (2011
49. [No authors listed] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324, 150-154 (1991
50. Molad, Y. et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11, 356-361 (2002 (Pubitemid 34760633)
51. Fessler, B. J. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473-1480 (2005 (Pubitemid 40663939)
52. Alarcon, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168-1172 (2007 (Pubitemid 47309732)
53. Ruiz-Irastorza, G. et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-583 (2006 (Pubitemid 44661744)
54. James, J. A. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16, 401-409 (2007 (Pubitemid 47122213)
55. Shinjo, S. K. et al. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum. 62, 855-862 (2010
56. Pons-Estel, G. J. et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res. (Hoboken) 62, 393-400 (2010
57. Wallace, D. J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 30, 1435-1436 (1987
58. Ho, K. T. et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44, 1303-1307 (2005 (Pubitemid 41487966)
59. Sisó, A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 17, 281-288 (2008 (Pubitemid 351655794)
60. Kaiser, R., Cleveland, C. M. & Criswell, L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68, 238-241 (2009
61. Tektonidou, M. G., Laskari, K., Panagiotakos, D. B. & Moutsopoulos, H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29-36 (2009
62. Jung, H. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863-868 (2010
63. Petri, M., Lakatta, C., Magder, L. & Goldman, D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am. J. Med. 96, 254-259 (1994 (Pubitemid 24099225)
64. Kavanaugh, A., Adams-Huet, B., Jain, R., Denke, M. & McFarlin, J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): A double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J. Clin. Rheumatol. 3, 3-8 (1997 (Pubitemid 27087947)
65. Borba, E. F. & Bonfa, E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28, 780-785 (2001 (Pubitemid 32246946)
66. Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis. Lupus 5 (Suppl. 1), S16-S22 (1996 (Pubitemid 26196736)
67. Pons-Estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830-839 (2009
68. Pons-Estel, G. J. et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: Data from a Latin-American cohort. Rheumatology (Oxford) http://dx.doi.org/10.1093/ rheumatology/ker514.
69. Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009
70. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann. Rheum. Dis. 69, 20-28 (2010
71. Schmajuk, G., Yazdany, J., Trupin, L. & Yelin, E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 386-392 (2010
72. Ruzicka, T., Sommerburg, C., Goerz, G., Kind, P. & Mensing, H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br. J. Dermatol. 127, 513-518 (1992
73. Cavazzana, I. et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 18, 735-739 (2009
74. Chang, A. Y. et al. Response to antimalarial agents in cutaneous lupus erythematosus: A prospective analysis. Arch. Dermatol. 147, 1261-1267 (2011
75. Rahman, P., Gladman, D. D. & Urowitz, M. B. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J. Rheumatol. 25, 1716-1719 (1998 (Pubitemid 28439264)
76. Jewell, M. L. & McCauliffe, D. P. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J. Am. Acad. Dermatol. 42, 983-987 (2000 (Pubitemid 30368665)
77. Kreuter, A. et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch. Dermatol. 145, 244-248 (2009
78. Leroux, G. et al. Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Ann. Rheum. Dis. 66, 1547-1548 (2007 (Pubitemid 350032673)
79. Wright, J. L., Tai, H., Wang, R., Wang, X. & Churg, A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L125-L133 (2007 (Pubitemid 46103438)
80. Lim, S. et al. Balance of matrix metalloprotease9 and tissue inhibitor of metalloprotease1 from alveolar macrophages in cigarette smokers. Regulation by interleukin10. Am. J. Respir. Crit. Care Med. 162, 1355-1360 (2000
81. Bermudez, E. A., Rifai, N., Buring, J. E., Manson, J. E. & Ridker, P. M. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 89, 1117-1119 (2002 (Pubitemid 34462860)
82. Lardet, D. et al. Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: Assessment in a prospective study [French]. Rev. Med. Interne 25, 786-791 (2004 (Pubitemid 40292251)
83. Wahie, S. et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: A retrospective cohort study. J. Invest. Dermatol. 131, 1981-1986 (2011
84. Turchin, I., Bernatsky, S., Clarke, A. E., St-Pierre, Y. & Pineau, C. A. Cigarette smoking and cutaneous damage in systemic lupus erythematosus. J. Rheumatol. 36, 2691-2693 (2009
85. Moghadam-Kia, S. et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch. Dermatol. 145, 255-260 (2009
86. Piette, E. W. et al. Impact of smoking in cutaneous lupus erythematosus. Arch. Dermatol. 148, 317-322 (2012
87. Parke, A. Antimalarial drugs and pregnancy. Am. J. Med. 85, 30-33 (1988
88. Parke, A. & West, B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J. Rheumatol. 23, 1715-1718 (1996 (Pubitemid 26342440)
89. Buchanan, N. M. et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann. Rheum. Dis. 55, 486-488 (1996 (Pubitemid 26249027)
90. Clowse, M. E., Magder, L., Witter, F. & Petri, M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640-3647 (2006 (Pubitemid 44737176)
91. Izmirly, P. M. et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69, 1827-1830 (2010
92. Levy, R. A. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: Double-blind and placebo-controlled study. Lupus 10, 401-404 (2001 (Pubitemid 32578614)
93. Costedoat-Chalumeau, N., Amoura, Z., Huong, D. L., Lechat, P. & Piette, J. C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111-115 (2005 (Pubitemid 40255619)
94. Wallace, D. J. in Dubois Lupus Erythematosus 7th edn (eds Wallace, D. J. & Hahn, B. H.) 1152-1176 (Lippincott Williams & Wilkins, Philadelphia, 2007
95. Van Beek, M. J. & Piette, W. W. Antimalarials. Dermatol. Clin. 19, 147-160, ix (2001
96. Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S. & Mieler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415-422 (2011
97. Venuturupalli, S. R., Gudsoorkar, V. S. & Wallace, D. J. Revisiting antimalarials in systemic lupus erythematosus: Developments of translational clinical interest. J. Rheumatol. (in press
98. Wallace, D. J. Advances in drug therapy for systemic lupus erythematosus. BMC Med. 8, 77 (2010
99. Wozniacka, A., Carter, A. & McCauliffe, D. P. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 11, 71-81 (2002 (Pubitemid 34259436)
100. Lopez, P., Gomez, J., Mozo, L., Gutierrez, C. & Suarez, A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res. Ther. 8, R42 (2006
101. Collinge, J. et al. Safety and efficacy of quinacrine in human prion disease (PRION1 study): A patient-preference trial. Lancet Neurol. 8, 334-344 (2009
102. Gurova, K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol. 5, 1685-1704 (2009
103. Adelusi, S. A. & Salako, L. A. Tissue and blood concentrations of chloroquine following chronic administration in the rat. J. Pharm. Pharmacol. 34, 733-735 (1982 (Pubitemid 12005630)
104. Ronnblom, L., Eloranta, M. L. & Alm, G. V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 54, 408-420 (2006 (Pubitemid 43228615)
105. Aman, M. J. et al. Interferon-α stimulates production of interleukin 10 in activated CD4+ T cells and monocytes. Blood 87, 4731-4736 (1996
106. Ronnblom, L., Alm, G. V. & Eloranta, M. L. The type I interferon system in the development of lupus. Semin. Immunol. 23, 113-121 (2011
107. Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538-552 (2011